We are live on ! Find out more
ZVRA icon

Zevra Therapeutics

33 hedge funds and large institutions have $104M invested in Zevra Therapeutics in 2015 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 8

14% more funds holding

Funds holding: 29 → 33 (+4)

13% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 8

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

2.09% less ownership

Funds ownership: 39.37% → 37.28% (-2.1%)

12% less capital inflows, than outflows

Capital inflows: $23.5M | Capital outflows: $26.9M

Holders
33
Holders Change
+4
Holders Change %
+13.79%
% of All Funds
0.92%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
12
Increased
9
Reduced
8
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

ZVRA Hedge Fund Activity: Q3 2015 in Review

33 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q3 2015, worth a combined $104M — up 1.4% from $103M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new ZVRA positions and 8 closed out — a net gain of 4 holders — while 9 added to existing stakes and 8 trimmed.

The largest buyer was Deerfield Management, adding an estimated $6.43M. The largest seller was Pentwater Capital Management, exiting entirely with an estimated $8.94M sold.

  • 33 institutional investors held Zevra Therapeutics (ZVRA) as of Q3 2015, up from 29 in Q2 2015.
  • Funds reported $104M of Zevra Therapeutics stock for Q3 2015, up 1.4% quarter-over-quarter.
  • 12 funds opened new Zevra Therapeutics positions in Q3 2015 and 8 closed out, a net change of +4 holders.
  • The largest Zevra Therapeutics buyer in Q3 2015 was Deerfield Management, an estimated $6.43M added.
  • The largest Zevra Therapeutics seller in Q3 2015 was Pentwater Capital Management, an estimated $8.94M sold.

Based on aggregated 13F filings for Q3 2015.